Great story and close to home.....

I have been aggressively buying Adalta (1AD) for former clients over recent months, and I am building a reasonable holding personally. I have always been intrigued by the company and whilst during the initial presentations from CEO, Samantha Cobb I little concept of the potential upside it is now perfectly clear.

Unfortunately this morning I was woken by a call just after 7am from one of my closest friends who told me her Father was on the verge of passing away from Idiopathic Pulmonary Fibrosis IPF and she was on a dash to Ireland to hopefully see him in time. IPF is a brutal terminal disease that leads to death normally within three years from diagnosis.

I am heading over to the Bioshares Conference on 21-22 July, and look forward to catching up with Sam and hopefully meeting some other of the key people involved. The up-front Pharma payments in fibrosis in particular can be significant and providing AD-114 is shown to be safe, the potential exists for multiple share price upside.

Rather than confuse you all here, I have attached my opinion piece I wrote in May this year.

[email protected]